The unbridled success of the Swiss Biotech industry continues apace
The Swiss biotech industry has reached record figures for 2017 in financing, infrastructure investment, and exports. This shows that confidence in its ability to create value and innovate remains unshaken. The most prominent example is the acquisition of Actelion by Johnson & Johnson, which, at almost USD 30 billion, was the largest stock exchange transaction worldwide within the life sciences industry over the past year.
The Swiss Biotech Association honors major industry achievements with Swiss Biotech Success Stories
On the occasion of its 20th anniversary, the Swiss Biotech Association launches Swiss Biotech Success Stories in recognition of the industry’s many accomplishments. Swiss Biotech Success Stories will grow over time to encompass all of the industry’s different facets. An independent jury of experts annually selects the laureates. The first recognitions go to Biogen, Glycart, Okairos, Selexis and Vifor Fresenius Medical Care Renal Pharma for their remarkable achievements and sustainable contributions to Switzerland and its biotech industry. Founders, scientists, investors and business partners celebrated the first laureates yesterday evening at this year’s Swiss Biotech Day.
The unbridled success of the Swiss Biotech industry continues apace - May 3, 2018 Ungebremster Höhenflug der Schweizer Biotech-Branche - 3. Mai 2018 Le secteur des biotechnologies a poursuivi son irrésistible ascension - le 3 mai 2018 Swiss Biotech Report presentation - May 3, 2018 Swiss Biotech Association honors major industry achievements with Swiss Biotech Success Stories - May 4, 2018 Die Swiss Biotech Association honoriert mit Swiss Biotech Success Stories die vielfältigen Branchenerfolge - 4. Mai 2018 La SBA honore les grandes réalisations de l'industrie en créant les Swiss Biotech Success Stories - 20180504